MX2023004829A - Compuestos, composiciones y metodos de uso para tratar fusiones espinales. - Google Patents

Compuestos, composiciones y metodos de uso para tratar fusiones espinales.

Info

Publication number
MX2023004829A
MX2023004829A MX2023004829A MX2023004829A MX2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A MX 2023004829 A MX2023004829 A MX 2023004829A
Authority
MX
Mexico
Prior art keywords
methods
compounds
compositions
treat spinal
spinal fusions
Prior art date
Application number
MX2023004829A
Other languages
English (en)
Spanish (es)
Inventor
Philip S Low
Stewart Low
Jeffery Nielsen
Original Assignee
Purdue Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Purdue Research Foundation filed Critical Purdue Research Foundation
Publication of MX2023004829A publication Critical patent/MX2023004829A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/29Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032Methine dyes, e.g. cyanine dyes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2023004829A 2020-10-26 2021-08-26 Compuestos, composiciones y metodos de uso para tratar fusiones espinales. MX2023004829A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063105678P 2020-10-26 2020-10-26
US202163193753P 2021-05-27 2021-05-27
PCT/US2021/047827 WO2022093374A1 (en) 2020-10-26 2021-08-26 Compounds,compositions and methods of use to treat spinal fusions

Publications (1)

Publication Number Publication Date
MX2023004829A true MX2023004829A (es) 2023-07-18

Family

ID=81383097

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004829A MX2023004829A (es) 2020-10-26 2021-08-26 Compuestos, composiciones y metodos de uso para tratar fusiones espinales.

Country Status (7)

Country Link
US (1) US20230390363A1 (https=)
EP (1) EP4232075A4 (https=)
JP (1) JP2023547889A (https=)
AU (1) AU2021369193A1 (https=)
CA (1) CA3196688A1 (https=)
MX (1) MX2023004829A (https=)
WO (1) WO2022093374A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019232285A1 (en) 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures
EP4719459A1 (en) * 2023-06-01 2026-04-08 Radius Health, Inc. Methods for identification and quantitation of abaloparatide and related peptide impurities

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018102616A1 (en) * 2016-11-30 2018-06-07 Purdue Research Foundation Fracture targeted bone regeneration through parathyroid hormone receptor stimulation
EP3765488A1 (en) * 2018-03-12 2021-01-20 Fresenius Kabi iPSUM S.r.l. Process for the manufacture of pthrp analogue
WO2019232285A1 (en) * 2018-05-30 2019-12-05 Purdue Research Foundation Targeting anabolic drugs for accelerated fracture repair
WO2022093373A1 (en) * 2020-10-26 2022-05-05 Purdue Research Foundation Compounds,compositions and methods of use to treat bone fractures

Also Published As

Publication number Publication date
WO2022093374A1 (en) 2022-05-05
CA3196688A1 (en) 2022-05-05
WO2022093374A8 (en) 2022-09-29
JP2023547889A (ja) 2023-11-14
AU2021369193A1 (en) 2023-06-01
EP4232075A4 (en) 2024-12-18
US20230390363A1 (en) 2023-12-07
EP4232075A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
MX2023004829A (es) Compuestos, composiciones y metodos de uso para tratar fusiones espinales.
PH12020550901A1 (en) Macrocyclic compounds for treating disease
MX2024006824A (es) Degradadores de la proteina transductora de se?al y activadora de la transcripcion 3 (stat3) y usos de los mismos.
CL2021003477A1 (es) Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8
SA522433087B1 (ar) Sos1 مثبطات
PH12021551409A1 (en) Kif18a inhibitors
MX2021007104A (es) Inhibidores de kif18a.
ECSP22098041A (es) Inhibidores alostéricos de egfr y métodos de uso de estos
MX2021005887A (es) Compuestos de 2-formil-3-hidroxifeniloximetilo capaces de modular hemoglobina.
EA201992878A1 (ru) Соединения для лечения болезни хантингтона
MX2020008767A (es) Disruptores del dímero egfr y uso de estos.
CO2021002977A2 (es) Dimetilaminoazetidinaminas como inhibidores de jak
SG10201811841UA (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201791018A1 (ru) Производные 6-амино-7-бицикло-7-деазапурина в качестве ингибиторов протеинкиназы
MX2020012799A (es) Composicion y metodo para tratar el cancer asociado con mutacion del egfr.
EA201892225A1 (ru) АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
BR112016016870A2 (pt) Derivados de icariina, seus usos, e composição farmacêutica
PH12017502123A1 (en) Substituted benzamides and methods of use thereof
PH12018502337A1 (en) Tetrahydropyrimidodiazepine and tetrahydropyridodiazepine compounds for treating pain and pain related conditions
MX2024012294A (es) RECEPTORES DE TGF-ß Y MÉTODOS DE USO
MX2023004796A (es) Compuestos, composiciones y metodos de uso para tratar fracturas oseas.
MX385698B (es) Uso de un compuesto que comprende un grupo pirrolidinilo y pirimidinilo para tratar enfermedades oculares
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.
PH12022551371A1 (en) Macrocycles for use in treating disease
GEAP202516674A (en) Indazole macrocycles and their use